Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Fisher Asset Management LLC Has $6.75 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE
04:20am, Friday, 05'th Dec 2025
Fisher Asset Management LLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) by 10.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Ex
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 04'th Dec 2025
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
03:23pm, Wednesday, 03'rd Dec 2025
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
03:13am, Wednesday, 03'rd Dec 2025
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
CENTURY LITHIUM ACHIEVES HIGH RECOVERY OF RARE EARTH AND CRITICAL ELEMENTS FROM PRIMARY LEACH SOLUTIONS
08:30am, Tuesday, 02'nd Dec 2025
VANCOUVER, BC , Dec. 2, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to report positive results from its ongoin
Campbell & CO Investment Adviser LLC Makes New $309,000 Investment in Ultragenyx Pharmaceutical Inc. $RARE
03:51am, Tuesday, 18'th Nov 2025
Campbell and CO Investment Adviser LLC bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in the second quarter, according to its most recent disclosure with the SEC. The firm boug
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
11:51am, Wednesday, 05'th Nov 2025
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
12:26am, Wednesday, 05'th Nov 2025
Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Fo
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings
06:31pm, Tuesday, 04'th Nov 2025
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street e
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
06:16pm, Tuesday, 04'th Nov 2025
Ultragenyx (RARE) came out with a quarterly loss of $1.81 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.4 per share a year ago.
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 t
Ethic Inc. Takes $241,000 Position in Ultragenyx Pharmaceutical Inc. $RARE
04:08am, Friday, 31'st Oct 2025
Ethic Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,603 s
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
09:00am, Thursday, 30'th Oct 2025
ENCINITAS, Calif. and WASHINGTON D.C.
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
04:30pm, Tuesday, 28'th Oct 2025
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
11:08am, Tuesday, 28'th Oct 2025
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
